SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Indications -- Sepsis/Acute Inflammation
An SI Board Since September 2001
Posts SubjectMarks Bans
89 16 0
Emcee:  scaram(o)uche Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
64First patient dosed in AZN’s CytoFab sepsis trial: siliconinvestor.comDewDiligence_on_SI-1/22/2008
63Heme oxygenase-1–derived carbon monoxide enhances the host defense response to mtnsaf-1/7/2008
62Antithrombin Inhibits Lipopolysaccharide-Induced TNF-Alpha Production by MonocytDewDiligence_on_SI-12/21/2007
61Protherics PLC announces AstraZeneca GBP10m Milestone London, UK; Brentwood, TNnigel bates-3/12/2007
60LLY to Run Xigris Trial to Satisfy EU Demand: investorshub.comDewDiligence_on_SI-2/26/2007
59Nautilus Biotech and Creabilis Therapeutics Achieve Technical Milestone in Collanigel bates-11/14/2006
58More on the same story from Reuters: investorshub.comDewDiligence_on_SI-11/3/2006
57Protherics PLC and AstraZeneca Updates CytoFab(TM) Development Programme Friday nigel bates-11/3/2006
56FDA Approves NovoSeven in <i>Acquired</i> Hemophilia: investorshub.DewDiligence_on_SI-10/17/2006
55Protherics Plc announces Publication of CytoFab(R) Phase 2b Data in Leading Journigel bates-9/5/2006
5435th Critical Care Congress of the Society of Critical Care Medicine (SCCM) Sandr.praveen-8/6/2006
53Any comments on the subset data from the KyberSept study? investorshub.com TheDewDiligence_on_SI-6/11/2006
52Nicotine analogues as potential sepsis therapies - nature.com <i>Importanigel bates-6/11/2006
51Lack Of A Key Enzyme Dramatically Increases Resistance To Sepsis Article Date:LJM-4/25/2006
50Critical Therapeutics Announces Abstracts Presented at European Molecular Biolognigel bates-2/17/2006
49Excess Circulating Angiopoietin-2 May Contribute to Pulmonary Vascular Leak in Snigel bates-2/14/2006
48Enanta Pharmaceuticals Announces Initiation of Phase 2 Studies in North America John McCarthy-1/19/2006
47Thanks Tuck - AshleyA.J. Mullen-12/9/2005
46OT Ashley, The Hart-Scott-Rodino act specifies a certain length of time duringtuck-12/9/2005
4520%. That is impressive. Congratulations, I remember looking at Protherics yeaA.J. Mullen-12/9/2005
44Critical Therapeutics Achieves Collaboration Milestone in HMGB1 Program Message nigel bates-12/8/2005
43Protherics and AstraZeneca Announce Late Stage Licensing Agreement On CytoFab(TMnigel bates-12/8/2005
42J Rheumatol. 2005 Sep;32(9):1821-31. Expression of human endogenous retrovirusscaram(o)uche-10/13/2005
41Eisai Announce Phase II Results, Plans to Initiate Phase III Clinical Trial Prognigel bates-8/29/2005
40[In vivo delivery of Caspase 8 or Fas siRNA improves the survival of septic micetuck-6/24/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News